Insider Buying: Altimmune (NASDAQ:ALT) CEO Acquires 20,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CEO Jerome Benedict Durso acquired 20,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was purchased at an average cost of $3.54 per share, with a total value of $70,800.00. Following the transaction, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. This trade represents a 160.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Jerome Benedict Durso also recently made the following trade(s):

• On Monday, December 22nd, Jerome Benedict Durso bought 12,500 shares of Altimmune stock. The stock was purchased at an average cost of $4.13 per share, for a total transaction of $51,625.00.

Altimmune Trading Up 0.9%

Shares of NASDAQ:ALT opened at $3.54 on Monday. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $7.73. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The company has a market capitalization of $399.43 million, a P/E ratio of -3.50 and a beta of 0.13. The company has a 50-day simple moving average of $4.48 and a 200 day simple moving average of $4.29.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. Sell-side analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. SBI Securities Co. Ltd. increased its position in Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after buying an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the period. Concurrent Investment Advisors LLC grew its stake in shares of Altimmune by 10.4% in the fourth quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after acquiring an additional 2,500 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after acquiring an additional 2,748 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Altimmune by 4.0% during the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after acquiring an additional 3,047 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Barclays began coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday. Finally, B. Riley Financial cut their target price on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Friday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.60.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.